News room - Egetis Therapeutics

23 August, 2022 Egetis to participate at upcoming investor conferences News Corporate Information Other Corporate Information English IR Optional

19 August, 2022 Interim report Q2 2022 News English Regulatory MAR VPML Report Interim Q2 IR Optional

18 August, 2022 Save the Date: Egetis to host a Capital Markets Day in Stockholm on October 13, 2022 News Corporate Information Nomination Committee English IR Optional

10 August, 2022 Egetis establishes subsidiary in the United States News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate

13 July, 2022 Egetis receives positive opinion on orphan designation for Aladote® from the European Medicines Agency for the Prevention of Acute Liver Failure News Corporate Information Other Corporate Information English IR Optional mfn-cus-aladote

20 June, 2022 Egetis appoints Sara Melton as President of North America News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate

31 May, 2022 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional

30 May, 2022 Bulletin from Egetis Therapeutics’ Annual General Meeting 2022 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional

19 May, 2022 Egetis Therapeutics raises approximately SEK 180 million through an oversubscribed rights issue News Corporate Action Shares Issuance English Regulatory MAR IR Optional

6 May, 2022 Egetis invites shareholders to an informal information meeting News Corporate Information Other Corporate Information English IR Optional

5 May, 2022 Egetis initiates build-up of medical affairs and the commercial team with the appointment of three senior leaders News Corporate Information Other Corporate Information English IR Optional

28 April, 2022 Egetis Therapeutics publishes prospectus relating to the Rights Issue News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional

26 April, 2022 Interim report January-March 2022 News English Regulatory MAR Report Interim Q1 IR Optional

20 April, 2022 Egetis Therapeutics’ 2021 annual report published News English Regulatory VPML Report Annual IR Optional

13 April, 2022 Bulletin from extraordinary shareholders’ meeting in Egetis Therapeutics AB and publication of timetable relating to the rights issue News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional

6 April, 2022 Egetis announces that the recruitment target has been met in the Emcitate® Triac Trial II study News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate

24 March, 2022 Egetis receives positive EMA opinion for orphan designation of Emcitate for treatment of Resistance to Thyroid Hormone type beta (RTH-β) News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate

21 March, 2022 NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional

21 March, 2022 Egetis Therapeutics resolves on a fully guaranteed preferential rights issue of approximately SEK 180 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional

14 March, 2022 Egetis announces participation at upcoming conferences News Corporate Information Other Corporate Information English IR Optional

24 February, 2022 Egetis Therapeutics asks for hugs to increase disease awareness of MCT8 deficiency News English PR Optional mfn-cus-emcitate

18 February, 2022 FDA grants Orphan Drug Designation to Emcitate® for treatment of Resistance to Thyroid Hormone type beta (RTH-β) News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate

17 February, 2022 Significant progress towards Emcitate® marketing applications in the US and Europe in 2023 News English Regulatory MAR Report Interim Yearend IR Optional

26 January, 2022 Egetis secures conditional acceptance for Emcitate® as brand name in the US News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate

25 January, 2022 Egetis appoints Karl Hård as Head of Investor Relations and Communication News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate

Press releases

2022

Calendar and upcoming reports

Contact us

Press releases

2022

Calendar and upcoming reports

Subscribe

Contact us